| OXIGENE, INC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110110940 | Methods for Enhancing the Efficacy of Vascular Disrupting Agents - This invention relates to methods for treating, preventing and/or managing cancer in a subject including enhancing the efficacy of a Vascular Disrupting Agent (e.g., a combretastatin or derivative thereof) by administering to the subject an α4β1 integrin antagonist sequentially or simultaneously in combination with said Vascular Disrupting Agent. | 05-12-2011 |
| 20090192098 | METHOD FOR TREATING HEMATOPOIETIC NEOPLASMS - This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent. | 07-30-2009 |
| 20090137687 | Compositions and Methods With Enhanced Therapeutic Activity - This invention relates to novel tricyclic quinone and catechol compositions, compositions containing prodrugs of tricyclic quinone and catechol compositions, and methods of use for the treatment of solid tumor cancers and other vascular proliferative disorders. In certain aspects, the compositions of the invention are capable of generating both a vascular targeting effect and tumor cell cytotoxicity (e.g., by oxidative stress) in order to achieve an enhanced anti-tumor response in a patient. | 05-28-2009 |
